|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
472.24 Million
|
|
CAGR (2025-2030)
|
16.83%
|
|
Fastest Growing Segment
|
Spinal
Muscular Atrophy (SMA)
|
|
Largest Market
|
West India
|
|
Market Size (2030)
|
USD 1,203.38 Million
|
Market Overview
India Gene Therapy Market was valued at USD
472.24 Million in 2024 and is expected to reach USD 1,203.38 Million by 2030
with a CAGR of 16.83% during the forecast period.
The India gene
therapy market is experiencing significant growth, driven by advancements in
biotechnology, increasing prevalence of genetic disorders, and government
initiatives to support healthcare innovation. The rising incidence of inherited
conditions such as Spinal Muscular Atrophy (SMA), Beta-Thalassemia, and various
types of cancers has spurred the demand for gene therapies as potential
treatments. Key technologies like CRISPR-Cas9 and other gene-editing tools are
enabling precise, effective therapies, further fueling market growth.
Additionally, the increasing investment in biotechnology research and
collaborations between pharmaceutical companies and academic institutions are
accelerating the development of new gene therapies.
However, the market also faces several challenges. One
of the major barriers is the high cost of gene therapies, which limits patient
access, particularly in lower-income segments of the population. Although the
Indian government is promoting the development of biotech innovations, there
are still regulatory hurdles that slow the approval process for new therapies.
Furthermore, a lack of sufficient infrastructure and expertise in some regions
can hinder the widespread adoption of gene therapies, particularly in rural and
underserved areas. Despite these challenges, the market is expected to continue
expanding as solutions to these issues evolve, making gene therapies more
accessible and affordable in the long term.
Key Market Drivers
Growing
Healthcare Infrastructure
India's growing healthcare infrastructure is one of
the key drivers for the advancement of various healthcare markets, including
gene therapy. As the nation continues to invest in and develop its healthcare
system, it creates a conducive environment for innovations in treatment,
including the adoption of advanced therapies like gene therapy. A robust
healthcare infrastructure ensures better access to medical services across both
rural and urban areas, facilitating the implementation of cutting-edge therapies
and technologies. As of March 31, 2023, India boasts a total of 1,69,615
Sub-Centres (SCs), 31,882 Primary Health Centres (PHCs), 6,359 Community Health
Centres (CHCs), 1,340 Sub-Divisional/District Hospitals (SDHs), 714 District
Hospitals (DHs), and 362 Medical Colleges (MCs). These facilities collectively
serve both rural and urban populations, ensuring widespread access to
healthcare services.
The expansion of healthcare infrastructure is further
complemented by a significant workforce of healthcare professionals. This
growing pool of doctors, specialists, nurses, and paramedical staff is crucial
for the successful implementation of new therapies, as it ensures the
availability of skilled personnel to deliver treatments effectively. The
healthcare workforce includes 2,39,911 Health Workers (Male + Female) at SCs,
40,583 Doctors/Medical Officers at PHCs, 26,280 Specialists & Medical
Officers at CHCs, and 45,027 Doctors and Specialists at SDHs and DHs.
Additionally, there are 47,932 Staff Nurses at PHCs, 51,059 Nursing Staff at
CHCs, and 1,35,793 Paramedical Staff at SDHs and DHs across India.
In addition to the healthcare workforce, the country’s
growing public expenditure on healthcare plays a pivotal role in boosting
healthcare infrastructure. Increased government spending on healthcare not only
improves the quality of existing facilities but also facilitates the
introduction of advanced medical technologies and treatments. India’s public
expenditure on healthcare reached 1.9% of GDP in FY24, up from 1.6% in FY23,
and the Health Ministry aims to reach 2.5% by FY25, further supporting the
enhancement of healthcare infrastructure and the accessibility of advanced
medical treatments.
The healthcare infrastructure growth in India is
poised to accelerate, with the Indian healthcare market projected to grow
significantly. This expansion is essential for fostering a healthcare
environment that can support the increasing demand for innovative treatments
such as gene therapy, ensuring better accessibility and improved outcomes for
patients across the country. The Indian healthcare market, valued at US$ 110
billion in 2016, is expected to reach US$ 638 billion by 2025, reflecting the
rapid growth of the healthcare sector and the continued investment in
infrastructure to support this expansion.
Increasing
Prevalence of Genetic Disorders
The increasing prevalence of genetic
disorders in India is a significant driver for the growth of the gene therapy
market. India, with its vast and diverse population, faces a rising burden of
genetic diseases, many of which are inherited and affect individuals from an
early age. Disorders such as Spinal Muscular Atrophy (SMA), Beta-Thalassemia,
Sickle Cell Disease (SCD), Cystic Fibrosis, and various genetic forms of cancer
are becoming more prevalent, which is raising awareness about the need for
innovative treatments like gene therapy. The country's large burden of genetic
disorders, particularly in rural and underserved areas, places a significant
strain on the healthcare system, highlighting the urgency for more effective
and accessible therapies.
As genetic testing becomes more
widespread and affordable, early detection rates have increased, bringing to
light the growing number of individuals affected by these conditions. With the
healthcare system becoming more attuned to genetic disorders, there is a
greater recognition of the potential for gene therapy to provide long-term
solutions, moving beyond traditional treatments like blood transfusions or bone
marrow transplants.
Furthermore, the rise in
lifestyle-related conditions that have a genetic component, such as certain
cancers, is contributing to the demand for gene therapies. This growing
awareness and prevalence of genetic disorders are encouraging more investment
in research, clinical trials, and the development of gene therapy solutions
tailored to the specific needs of the Indian population. Consequently, as the
need for advanced treatments continues to rise, gene therapy presents itself as
a promising solution, driving market expansion.
Download Free Sample Report
Key Market Challenges
Regulatory
and Approval Delays
Workforce shortages in healthcare
represent a significant challenge for the India Gene Therapy Market, as the demand
for health check-up services continues to rise. The shortage of qualified
healthcare professionals, including physicians, nurses, technicians, and
administrative staff, is a key barrier to the efficient delivery of preventive
healthcare services and the expansion of health check-up offerings across the
Kingdom.
One of the primary issues contributing
to workforce shortages in Saudi Arabia's healthcare sector is the imbalance
between the growing demand for healthcare services and the limited supply of
skilled professionals. As the population ages and the prevalence of chronic
diseases such as diabetes, heart disease, and hypertension rises, the need for
regular health check-ups and preventive care has intensified. However, the
healthcare workforce is often stretched thin, unable to meet the increasing
demand for these services. This strain on resources leads to longer wait times,
reduced quality of care, and, in some cases, compromised patient safety.
Moreover, the specialized skills
required to administer comprehensive health check-ups—including diagnostic
screenings, laboratory tests, imaging, and consultations with
specialists—demand highly trained personnel. The lack of sufficient numbers of
qualified professionals, particularly in rural and remote areas, further
exacerbates the challenge. In many regions, patients may face difficulty
accessing timely health check-ups due to the limited availability of trained
staff, hindering the ability to meet the rising demand for preventive
healthcare.
Key Market Trends
Advancements
in Biotechnology and Gene Editing
Advancements in Biotechnology and Gene Editing are
emerging as key trends driving the growth of the gene therapy market in India.
As technological innovation accelerates globally, India is benefiting from
cutting-edge biotechnology and gene-editing technologies that enable the
development of more effective and targeted treatments for genetic disorders.
Tools like CRISPR-Cas9 and Zinc Finger Nucleases (ZFNs) are at the forefront of
gene editing, offering unprecedented precision in altering genes to correct genetic
defects or treat various diseases.
In India, these advancements are particularly
impactful in the context of genetic disorders such as Spinal Muscular Atrophy
(SMA), Beta-Thalassemia, and Sickle Cell Disease (SCD), where gene therapy
offers the potential for curative treatments rather than merely managing
symptoms. The increased focus on biotechnology has led to the establishment of
several biotech research hubs and institutions across the country, particularly
in cities like Bengaluru, Hyderabad, and Mumbai, where research and development
efforts are geared toward advancing gene therapy technologies.
Indian biotech companies are actively investing in the
development of gene editing tools, bringing together expertise from global and
local stakeholders to create therapies tailored to the Indian population. The
growing collaboration between Indian pharmaceutical companies and international
biotech firms is also contributing to advancements in gene therapy. This trend
is supported by government initiatives, including funding for biotechnology
research and efforts to strengthen intellectual property protections for
innovations in the gene editing space.
Segmental Insights
Indication
Insights
Based on Indication, Spinal Muscular
Atrophy (SMA) emerged as the fastest growing segment in the India Gene
Therapy Market in 2024. due to a combination of factors, including the rising
incidence of the disease, increased awareness, and the availability of
innovative treatment options. SMA is a rare, genetically inherited disorder
that leads to the progressive degeneration of motor neurons, causing muscle
weakness and atrophy. The disease has a significant impact on children, with
the most severe form manifesting in infancy, making it a critical area for
intervention.
Recent advancements in gene therapy have brought
breakthrough treatments for SMA, such as Onasemnogene abeparvovec
(Zolgensma), which has shown promise in altering the course of the disease by
addressing the root cause at the genetic level. The introduction of such
therapies has generated increased interest in SMA treatment options, leading to
heightened demand for gene therapies in India. In addition, India’s healthcare system
has made significant strides in the diagnosis and management of rare diseases
like SMA, with improved genetic screening and early detection efforts helping
identify affected individuals more rapidly.
Vector
Type Insights
Based on Vector Type, Adeno-Associated
Virus (AAV have emerged as the fastest growing segment in the India Gene
Therapy Market during the forecast period. This is due to their
superior characteristics, which make them an ideal choice for gene delivery in
the treatment of a wide range of genetic disorders. AAV vectors are gaining
widespread adoption in gene therapy because of their ability to infect a broad
spectrum of cell types, their low immunogenicity, and their potential to
provide long-term, stable gene expression with minimal side effects. These
attributes are crucial for treating genetic conditions such as Spinal Muscular
Atrophy (SMA), Hemophilia, and Retinal Diseases, where precise and durable
therapeutic outcomes are required.
In India, the rise in demand for AAV-based gene
therapies can be attributed to the increasing prevalence of genetic disorders
and a growing awareness of advanced treatment options. As healthcare
infrastructure continues to improve, particularly in specialized treatment
centers, AAV's safety profile and its proven effectiveness in clinical trials
have made it the preferred vector for developers targeting complex and rare
diseases. Additionally, as India’s biotechnology and pharmaceutical sectors
continue to evolve, AAV technology has benefited from increased research and
development investments, further driving its growth.
Download Free Sample Report
Regional Insights
Based on Region, West India emerged
as the dominating region in the India Gene Therapy Market in 2024. This is due to several
key factors, including its well-established healthcare infrastructure, strong
presence of biotech and pharmaceutical companies, and robust research and
development (R&D) ecosystem. Cities like Mumbai, Pune, and Ahmedabad are
key hubs for healthcare and biotechnology in India, making the region a focal
point for advancements in gene therapy. Mumbai, as the financial capital,
attracts significant investments in healthcare innovation, and many leading
global pharmaceutical and biotech companies have set up operations in the
region, contributing to the development of gene therapies.
The region’s high concentration of medical research
institutions and clinical trial centers also plays a crucial role in fostering
the growth of gene therapy. West India hosts several renowned universities and
research organizations specializing in genetics, molecular biology, and
biotechnology, creating a talent pool that drives innovation in gene therapy.
Additionally, Mumbai’s position as a healthcare services hub offers access to
state-of-the-art diagnostic centers and medical facilities, which support the
diagnosis and treatment of genetic disorders, further facilitating the growth
of gene therapy solutions.
Recent Development
- In January 2025, Immuneel, a pioneering
cell and gene therapy startup, has unveiled its CAR-T cancer therapy in India.
This breakthrough therapy, designed to target and eliminate cancerous cells,
offers a new avenue for treating certain types of blood cancers. The launch
marks a significant step forward in India’s oncology treatment landscape,
demonstrating the country's growing expertise in advanced biotherapeutic
solutions.
- In July 2024, Biomedical firm Miltenyi
Biotec partnered with THSTI (Translational Health Science and Technology
Institute) to pioneer cell and gene therapy research in India. The
collaboration aims to revolutionize cancer care by making innovative therapies
more affordable and accessible. By combining Miltenyi Biotec’s advanced
technologies with THSTI’s research capabilities, the partnership strives to
accelerate the development of cutting-edge treatments for cancer, ultimately
improving patient outcomes and expanding access to life-saving therapies across
the country.
- In June 2024, Indian officials have
announced significant progress in developing gene therapy for sickle cell
disease, a hereditary blood disorder. The therapy, being developed through
collaboration between research institutions and biotech companies, aims to
offer a curative treatment for patients suffering from this life-threatening
condition. India’s advancements in genetic research, combined with cutting-edge
gene-editing technologies, are bringing the country closer to addressing the
high prevalence of sickle cell disease, particularly in tribal and rural areas,
offering new hope for affected individuals.
- In April 2024, Smt. Droupadi Murmu, the
President of India, inaugurated the country’s first home-grown gene therapy for
cancer at IIT Bombay. This groundbreaking therapy, developed by Indian
scientists, offers new hope in the fight against cancer. The innovation marks a
significant milestone in India's biotechnology sector, showcasing the nation's
growing capabilities in advanced healthcare and gene-based treatments.
Key Market Players
- Novartis
India Ltd.
- Bharat
Biotech
- Cipla Limited
- Zydus
Group
- Biocon
Limited
- Dr.
Reddy's Laboratories
- Intas
Pharmaceuticals Ltd.
- Sun
Pharmaceutical Industries Ltd.
- Serum
Institute of India
- Panacea
Biotec
|
By Indication
|
By Vector Type
|
By Route of Administration
|
By Region
|
- Large B-Cell Lymphoma
- Multiple Myeloma
- Spinal Muscular Atrophy (SMA)
- Acute Lymphoblastic Leukemia (ALL)
- Melanoma (lesions)
- Inherited Retinal Disease
- Beta-Thalassemia Major/SCD
- Others
|
- Lentivirus
- RetroVirus & gamma RetroVirus
- AAV
- Modified Herpes Simplex Virus
- Adenovirus
- Others
|
|
- East India
- West India
- North India
- South India
|
Report Scope
In this report, the India Gene Therapy Market has
been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- India Gene Therapy Market, By Indication:
o Large B-Cell Lymphoma
o Multiple Myeloma
o Spinal Muscular Atrophy (SMA)
o Acute Lymphoblastic Leukemia (ALL)
o Melanoma (lesions)
o Inherited Retinal Disease
o Beta-Thalassemia Major/SCD
o Others
- India Gene Therapy Market, By Vector Type:
o Lentivirus
o RetroVirus & gamma RetroVirus
o AAV
o Modified Herpes Simplex Virus
o Adenovirus
o Others
- India Gene Therapy Market, By Route of
Administration:
o Intravenous
o Others
- India Gene Therapy Market,
By Region:
o East India
o West India
o North India
o South India
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the India Gene Therapy Market.
Available Customizations:
India Gene Therapy Market report with the given
market data, TechSci Research offers customizations according to a company's
specific needs. The following customization options are available for the
report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
India Gene Therapy Market is an upcoming report to
be released soon. If you wish an early delivery of this report or want to
confirm the date of release, please contact us at sales@techsciresearch.com